Form 4: Dermata CFO Acquires Shares, Warrants in Private Placement

Dermata Therapeutics' SVP and CFO, Kyri K. Van Hoose, acquired common stock and warrants in a private placement, adjusting an existing warrant's exercise price.

Summary

• Kyri K. Van Hoose, SVP and CFO of Dermata Therapeutics, Inc. (DRMA), acquired 122,549 shares of common stock and accompanying warrants in a private placement.
• The private placement included 122,549 Series C warrants and 122,549 Series D warrants, each allowing the purchase of one share of common stock.
• The purchase price for each share of common stock and its accompanying warrants was $2.04.
• An existing warrant, issued on January 3, 2025, with an exercise price of $12.70, was amended to an exercise price of $2.04 in connection with the private placement. This involved the cancellation of 7,874 old warrants and the purchase of 7,874 replacement warrants.
• The reported transactions reflect a one-for-10 reverse stock split effected by the Issuer on August 1, 2025.

Sentiment

Score: 6

Explanation: The insider's participation in a private placement, acquiring a substantial number of shares and warrants, suggests a degree of confidence in the company's future. However, the prior reverse stock split and the need for stockholder approval for warrant exercisability introduce some caution.

Positives

• SVP and CFO Kyri K. Van Hoose participated in a private placement, acquiring a significant number of shares and warrants, which may signal management confidence in the company's future.
• The amendment of an existing warrant's exercise price from $12.70 to $2.04 makes it significantly more 'in the money' or closer to it, potentially increasing its value and the likelihood of exercise.

Negatives

• The one-for-10 reverse stock split effected on August 1, 2025, often indicates a company's stock price has fallen significantly, potentially to avoid delisting or to make the stock more attractive to institutional investors.

Risks

• The exercisability of the newly acquired Series C and Series D warrants is contingent upon stockholder approval of the issuance of the underlying common stock.
• The reporting person cannot exercise the warrants if, after giving effect to the exercise, they would beneficially own more than 9.99% of the outstanding common stock, as determined by Section 13(d) of the Exchange Act.

Future Outlook

The exercisability of the Series C and Series D warrants is dependent on future stockholder approval, indicating a future corporate action is required for these securities to become fully active.

Management Comments

• The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement.
• Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock.
• The purchase price per share and accompanying warrants was $2.04.
• Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025.
• In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04.

Industry Context

This Form 4 primarily details an insider transaction and a capital raise through a private placement. It does not provide broader industry trends or competitive analysis. However, private placements and reverse stock splits are common mechanisms for smaller biotechnology or pharmaceutical companies (which Dermata Therapeutics appears to be, given its name) to raise capital and manage stock price, respectively.

Related Party Transactions

• The SVP and CFO, Kyri K. Van Hoose, acquired common stock and warrants directly from Dermata Therapeutics, Inc. in a private placement. This is a transaction between an officer of the company and the company itself.
• An existing warrant held by the SVP and CFO was also amended by the company.

Stakeholder Impact

• Shareholders: The private placement could lead to dilution if the warrants are exercised, increasing the total number of outstanding shares. The reverse stock split previously reduced the number of outstanding shares but increased the per-share price.

Next Steps

• Stockholder approval is required for the issuance of common stock underlying the Series C and Series D warrants to become exercisable.

Key Dates

Keywords

Dermata Therapeutics, DRMA, Form 4, insider trading, private placement, warrants, common stock, reverse stock split, Kyri K. Van Hoose, CFO, beneficial ownership